Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phagocytes are a diverse group of specialized immune cells (including neutrophils, monocytes, macrophages, dendritic cells, and others) that protect the body by engulfing and destroying foreign particles, pathogens, and dead or dying cells[1][3][7][8]. They play a critical role in both the innate and adaptive branches of the immune system by directly ingesting and neutralizing threats and by processing and presenting antigens to other immune cells[2][3][5]. There are "professional" phagocytes (with high efficiency, such as macrophages and neutrophils) and "non-professional" phagocytes (less efficient, such as fibroblasts)[3][5][9]. Phagocytes are essential for fighting infections, maintaining tissue health, and modulating immune responses[3][5][8]. They can contribute to disease if dysregulated, such as in chronic inflammation, immune evasion by cancer, or autoimmune conditions[1][2][5]. While not a druggable molecular target in itself, enhancing or inhibiting phagocyte function (such as with antibodies against CD47) is a current area of therapeutic research[1].
Enhancement of phagocytosis (e.g., via blockade of CD47 ‘don’t eat me’ signal)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phagocytes.